Bcl-2 oncogene (B cell lymphoma/leukemia-2) levels correlate with systemic lupus erythematosus disease activity

Anticancer Research

Volumn 19, Issue 4 B, 1999, Pages 3073-3076

  Miret, C ^a   Font, J ^a   Molina, Rafael ^a   Garcia Carrasco, M ^a   Filella, X ^a   Ramos, M ^a   Cervera, R ^a   Ballesta, A ^a   Ingelmo, M ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Activity; Apoptosis; Bcl 2; Glucocorticoids; Systemic lupus erythematosus

Indexed keywords

PROTEIN BCL 2;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; AUTOIMMUNITY; BLOOD LEVEL; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE TRANSLOCATION; HUMAN; LYMPHOCYTE; MAJOR CLINICAL STUDY; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; GENES, BCL-2; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED;

EID: 0033452425     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Monaghan P, Robertson D, Amos TAS, Dyer MJS, Mason DY, Greaves MF: Ultrastructural localization of bcl-2 protein. J Histochem Cytochem 40: 1819-1825, 1992.
2. Hockenbery DM, Zutter M, Hickey W Nahm M, Korsmeyer SJ: bcl-2 protein is topographically restricted in tissues characterized by apoptotic death. Proc Natl Acad Sci USA 88: 6961-6965, 1991.
3. Graninger WB, Seto M, Boutain B, Goldman P, Korsmeyer SJ: Expression of bcl-2 and bcl-2 Ig fusion transcripts in normal and neoplastic cells. J Clin Invest 80: 1512-1515, 1987.
4. LeBrun DP, Warnke RA, Cleary ML: Expression of bcl-2 in fetal tissues suggests a role in morphogenesis. Am J Pathol 142: 743-753, 1993.
5. Graninger WB, Smolen JS: Should the clinician have interest in the deregulation of apoptosis in autoimmunity? Br J Rheumatol 36: 1244-1246, 1997.
6. McDonnell T, Deane N, Platt F, Nunez G, Jaeger U, McKearn J: bcl-2 immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lyphoproliferation. Cell 57: 79-88, 1989.
7. Strasser A, Wittingham S, Vaux DL, Bath ML, Adams JM, Cory S: Enforced bcl-2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci USA 88: 8661-8665, 1991.
8. Nunez G, Hockenbery D, McDonnell TJ, Sorensen CM, Korsmeyer SJ: bcl-2 maintains B-cell memory. Nature 353: 71-73, 1991.
9. Hartley SB, Cooke MP, Fulcher DA, Harris AW, Cory S, Basten A, Elimination of self-reactive lymphocytes-B proceeds in 2 stages: arrested development and cell death. Cell 72: 325-335, 1994.
10. Aringer M, Wintersberger W, Steiner CW, Kiener H, Presterl E, Jaeger U, Smolen JS, Graninger WB: High levels of bcl-2 protein in circulating T lymphocytes, but not B lymphocytes, of patients with systemic lupus erythematosus. Arthritis Rheum 37: 1423-1430, 1991.
11. Kumagai S, Yanagida H, Tsujimoto Y: Increased expression of bcl-2 protein in neriDheral B cells of patients with svstemic IUDUS ervthematosus (abstract). Arthritis Rheum 36(suppl 9): S76, 1993.
12. Gatenby PA, Irvine M.. The bcl-2 proto-oncogene is overexpressed in systemic lupus erythematosus. J Autoimmun 7: 623-631, 1994.
13. Rose LM, Latchman DS, Isenberg DA: Apoptosis in peripheral lymphocytes in systemic lupus erythematosus: a review. Br J Rheumatol 36: 158-163, 1997.
14. Graninger WB: Transcriptional overexpression of the protooncogene bcl-2 in patients with systemic lupus erythematosus. Wien Klin Wochenschr 104: 205-207, 1992.
15. Chan EY, Ko SC, Lau SC: Increased rate of apoptosis and decreased expression of bcl-2 protein in peripheral blood lymphocytes from patients with active systemic lupus erythematosus. Asian Pac J Allergy Immunol 15: 3-7, 1997.
16. Rose LM, Latchman DS, Isenberg DA: bcl-2 expression is unaltered in unfractionated peripheral blood mononuclear cells in patients with systemic lupus erythematosus. Br J Rheumatol 340: 3160-3200, 1995.
17. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF: The 1982 revised criteria for classification of SLE. Arthritis Rheum 25: 1271-1272, 1982.
18. Bombardier C, Gladman DG, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE: Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 35: 630-640, 1992.
19. McLaughlin JR, Bombardier C, Farewell VT: Kidney biopsy in systemic lupus erythematosus. III. Survival analysis controlling for clinical and laboratory variables. Arthritis Rheum 37: 559-567, 1994.
20. Knipping E, Krammer PH, Onel KB, Lehman TJA, Mysler E, Elkon KB: Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum 38: 1735-1737, 1995.
21. Jodo S, Kovayashi S, Kayagaki N, Ogura N, Feng Y, Amasaki Y, Fujisaku A, Azuma M, Yagita H, Okumura K, Koike T: Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erytematosus (SLE) and other autoimmune diseases. Clin Exp Immunol 107: 89-95, 1997.
22. + cells of older lupus mice. Eur J Immunol 27: 1901-1910, 1997.
23. Mounth JD, Zhou T, Su X: Autoimmune disease results from multiple interactive defects in apoptosis induction molecules and signaling pathways. Behring Inst Mitt 99: 200-219, 1996.
24. Herrmann M, Zoller OM, Hagenhofer M, Voll R, Kalden JR; What triggers anti-dsDNA antibodies? Mol Biol Rep 23: 265-267, 1996.
25. Koh JS, Levine JS: Apoptosis and autoimmuity. Curr Opin Nephrol Hypertens 6: 259-266, 1997.
26. Kalden JR: Defective phagocytosis of apoptotic cells: possible explanation for the induction of autoantibodies in SLE. Lupus 6: 326-327, 1997.
27. Emlen W, Niebur J, Kadera R: ccelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 152: 3685-3692, 1994.
28. Lorenz HM, Grunke M, Hieronymus T, Herrmann M, Kuhnel A, Manger B, Kalden JR: In vitro apoptosis and expression of apoptosis-related molecules in lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases. Arthritis Rheum 40: 306-317, 1997.
29. Tsujimoto Y, Cossman J, Jaffe E, Croce CM: Involvement of the bcl-2 gene in human follicular lymphoma. Science 228; 1440-1443, 1985.
30. Monaghan P, Robertson D, Amos TAS, Dyer MJS, Mason DY, Greaves MF: Ultrastructural localization of bcl-2 protein. J Histochem Cytochem 40: 1819-1825, 1992.
31. Nakayama K, Negishi I, Kuida K, Shinkai Y, Louie MC, Fields LE, Lucas PJ: Disappearance of the lymphoid system in bcl-2 homozygous mutant chimeric mice. Science 261: 1584-1588, 1993.
32. Gratiot-Deans J, Ding LY, Turka LA, Nunez G: bcl-2 protooncogene expression during human T-cell development: evidence for biphasic regulation. J immunol 151: 83-917, 1993.
33. Katsumata M, Siegel RM, Louie DC, Miyashita T, Tsujimoto Y, Nowell PC: Differential effects of bcl-2 on T-cells and B-cells in transgenic mice. Proc Natl Acad Sci USA 89: 1137-1138, 1992.
34. Ohsako S, Hara M, Harigai M, Fukasawa C, Kashiwazaki S: Expression and function of Fas antigen and bcl-2 in human systemic lupus erythematosus lymphocytes. Clin Immunol Immunopathol 73: 109-114, 1994.
35. Kumagai S: Apoptosis and SLE. J Clin Exp Med 176: 314-319, 1996.